03 Apr 2019 --- Chr. Hansen’s establishment of a 50/50 joint venture together with Lonza in the live biotherapeutic products (LBPs) industry is the next phase in the evolution of how healthy bacteria are perceived. Announced yesterday, it will not change the nutrition & health focus at the Danish-headquartered company, however, with the JV not operating in the supplements or the probiotics/OTC domain. The focus will be on pharma-grade/GMP with defined strains.
